| Old Articles: <Older 43891-43900 Newer> |
|---|
 |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.   |
The Motley Fool
September 1, 2010
Eric Bleeker |
Why Apple Investors Should Be Excited About Today's Announcement Apple wants to control your living room. |
The Motley Fool
September 1, 2010
Jeremy Phillips |
Is Olin a Short? Does this highly-shorted stock deserve it? With a PEG ratio of less than 1.0, Olin looks attractively valued relative to its expected growth. |
The Motley Fool
September 1, 2010 |
Why We're Buying Seaspan There's a trend of booming international trade, but investing in the field is difficult. In fact, only about 5% of shippers are publicly traded. |
The Motley Fool
September 1, 2010
Seth Jayson |
Do Dynegy's Margins Measure Up? Here's the margin picture for Dynegy over the past few years. |
The Motley Fool
September 1, 2010
Toby Shute |
Rig Takeover Rumblings This rumor goes right to the source -- the potential acquirer himself! |
The Motley Fool
September 1, 2010
David Lee Smith |
Watch This Media Merger With a Close Eye The process hasn't been smooth sailing for Comcast/NBC Universal, but watch it carefully. |
The Motley Fool
September 1, 2010
Jeremy Phillips |
Is Trouble Ahead for CenturyLink? We compared CenturyLink's expected P/E ratio of the next 12 months relative to its 5-year estimated growth rate. |
The Motley Fool
September 1, 2010
Seth Jayson |
Will Pharmaceutical Product Development Disappoint Analysts Next Quarter? There's no foolproof way to know the future for Pharmaceutical Product Development or any other company. |
The Motley Fool
September 1, 2010
Eric Bleeker |
Why We're Buying Marvell Technologies The author explains why he thinks Marvell deserves a place in your portfolio. |
| <Older 43891-43900 Newer> Return to current articles. |
